Pediatric IBD Studies Should Assess Disease Activity, Panel Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.